Literature DB >> 14326082

PHARMACOLOGY OF KASUGAMYCIN AND THE EFFECT ON PSEUDOMONAS INFECTION.

T TAKEUCHI, M ISHIZUKA, H TAKAYAMA, K KUREHA, M HAMADA, H UMEZAWA.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS; BLOOD; METABOLISM; MICE; MONKEYS; PHARMACOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; TOXICOLOGIC REPORT; URINE

Mesh：

Substances：

Year:  1965        PMID： 14326082

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  5 in total

1.  Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis.

Authors:  Jae-Hyun Lee; Chang-Min Lee; Joyce H Lee; Mun-Ock Kim; Jin Wook Park; Suchitra Kamle; Bedia Akosman; Erica L Herzog; Xue Yan Peng; Jack A Elias; Chun Geun Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2022-09       Impact factor: 7.748

2.  Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19.

Authors:  Suchitra Kamle; Bing Ma; Chang Min Lee; Gail Schor; Yang Zhou; Chun Geun Lee; Jack A Elias
Journal:  Elife       Date:  2022-06-23       Impact factor: 8.713

3.  In vitro antibacterial activity of kasugamycin.

Authors:  A A Levitan
Journal:  Appl Microbiol       Date:  1967-07

4.  ksgA mutations confer resistance to kasugamycin in Neisseria gonorrhoeae.

Authors:  Paul M Duffin; H Steven Seifert
Journal:  Int J Antimicrob Agents       Date:  2008-12-18       Impact factor: 5.283

5.  The context of the ribosome binding site in mRNAs defines specificity of action of kasugamycin, an inhibitor of translation initiation.

Authors:  Yan Zhang; Nikolay A Aleksashin; Dorota Klepacki; Caleb Anderson; Nora Vázquez-Laslop; Carol A Gross; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 11.205
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.